{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:22:24Z","timestamp":1778545344591,"version":"3.51.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s43440-024-00664-8","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T01:02:38Z","timestamp":1730336558000},"page":"124-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Progress in the study of anti-tumor effects and mechanisms of vitexin"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7444-8954","authenticated-orcid":false,"given":"Qiming","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2665-1438","authenticated-orcid":false,"given":"Rui","family":"Huan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1008-2553","authenticated-orcid":false,"given":"Defeng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8662-5777","authenticated-orcid":false,"given":"Junwei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-6450","authenticated-orcid":false,"given":"Lei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"issue":"03","key":"664_CR1","first-page":"343","volume":"31","author":"R Xu","year":"2024","unstructured":"Xu R, Sun F, Tian X, REN Y, Meng NXINGQ. Interpretation of the key points of Cancer incidence and mortality inChina,2016. CJCTCS. 2024;31(03):343\u201356.","journal-title":"CJCTCS"},{"key":"664_CR2","doi-asserted-by":"crossref","unstructured":"Song ZY, Wu YY, Yang JB, Yang DQ, Fang XD. Progress in the treatment of advanced gastric cancer. TUMOR BIOL. 2017;39(7).","DOI":"10.1177\/1010428317714626"},{"key":"664_CR3","doi-asserted-by":"crossref","unstructured":"Li RX, Li Q, Ji Q. Molecular targeted study in tumors: from western medicine to active ingredients of traditional Chinese medicine. BIOMED PHARMACOTHER. 2020;121.","DOI":"10.1016\/j.biopha.2019.109624"},{"key":"664_CR4","doi-asserted-by":"crossref","unstructured":"Yang ZM, Zhang QH, Yu LH, Zhu JY, Cao Y, Gao XF. The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer. J Ethnopharmacol. 2021;264.","DOI":"10.1016\/j.jep.2020.113249"},{"key":"664_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.fitote.2016.09.011","volume":"115","author":"M He","year":"2016","unstructured":"He M, Min JW, Kong WL, He XH, Li JX, Peng BW. A review on the pharmacological effects of vitexin and isovitexin. Fitoterapia. 2016;115:74\u201385.","journal-title":"Fitoterapia"},{"key":"664_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.freeradbiomed.2021.05.028","volume":"171","author":"S Li","year":"2021","unstructured":"Li S, Liang T, Zhang Y, Huang K, Yang SY, Lv HY, et al. Vitexin alleviates high-fat diet induced brain oxidative stress and inflammation via anti-oxidant, anti-inflammatory and gut microbiota modulating properties. FREE RADICAL BIO MED. 2021;171:332\u201344.","journal-title":"FREE RADICAL BIO MED"},{"issue":"33","key":"664_CR7","first-page":"2565","volume":"7","author":"F An","year":"2012","unstructured":"An F, Yang GD, Tian JM, Wang SH. Antioxidant effects of the orientin and vitexin in <\u2009i\u2009>\u2009Trollius Chinensis\u2009Bunge in D-galactose-aged mice. NRR. 2012;7(33):2565\u201375.","journal-title":"NRR"},{"issue":"1","key":"664_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phymed.2015.11.003","volume":"23","author":"SIG Rosa","year":"2016","unstructured":"Rosa SIG, Rios-Santos F, Balogun SO, Martins DTD. Vitexin reduces neutrophil migration to inflammatory focus by down-regulating pro-inflammatory mediators via inhibition of p38, ERK1\/2 and JNK pathway. Phytomedicine. 2016;23(1):9\u201317.","journal-title":"Phytomedicine"},{"issue":"12","key":"664_CR9","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1016\/j.fct.2011.09.040","volume":"49","author":"LY Dong","year":"2011","unstructured":"Dong LY, Fan YF, Shao X, Chen ZW. Vitexin protects against myocardial ischemia\/reperfusion injury in Langendorff-perfused rat hearts by attenuating inflammatory response and apoptosis.FOOD. CHEM TOXICOL. 2011;49(12):3211\u20136.","journal-title":"CHEM TOXICOL"},{"issue":"3","key":"664_CR10","first-page":"224","volume":"69","author":"HG Je","year":"2014","unstructured":"Je HG, Hong SM, Je HD, Sohn UD, Choi YS, Seo SY, et al. The inhibitory effect of vitexin on the agonist-induced regulation of vascular contractility. Pharmazie. 2014;69(3):224\u20138.","journal-title":"Pharmazie"},{"key":"664_CR11","doi-asserted-by":"crossref","unstructured":"Zhang S, Zhang SX, Wang H, Chen Y. Vitexin ameliorated diabetic nephropathy via suppressing GPX4-mediated ferroptosis. EUR J PHARMACOL. 2023;951.","DOI":"10.1016\/j.ejphar.2023.175787"},{"key":"664_CR12","doi-asserted-by":"crossref","unstructured":"Venturini CL, Macho A, Arunachalam K, de Almeida DAT, Rosa SIG, Pavan E et al. Vitexin inhibits inflammation in murine ovalbumin-induced allergic asthma.BIOMED PHARMACOTHER. 2018;97:143\u201351.","DOI":"10.1016\/j.biopha.2017.10.073"},{"issue":"2","key":"664_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1747-0285.2012.01400.x","volume":"80","author":"E Abbasi","year":"2012","unstructured":"Abbasi E, Nassiri-Asl M, Shafeei M, Sheikhi M. Neuroprotective effects of Vitexin, a Flavonoid, on Pentylenetetrazole-Induced seizure in rats. CHEM BIOL DRUG DES. 2012;80(2):274\u20138.","journal-title":"CHEM BIOL DRUG DES"},{"issue":"7","key":"664_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2174\/1568009043332763","volume":"4","author":"S Fulda","year":"2004","unstructured":"Fulda S, Klaus-Michael D. Targeting apoptosis pathways in cancer therapy. CANCER DRUG TAR. 2004;4(7):569\u201376.","journal-title":"CANCER DRUG TAR"},{"issue":"3","key":"664_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11912-022-01199-y","volume":"24","author":"P Singh","year":"2022","unstructured":"Singh P, Lim B. Targeting apoptosis in Cancer. CURR ONCOL REP. 2022;24(3):273\u201384.","journal-title":"CURR ONCOL REP"},{"key":"664_CR16","doi-asserted-by":"crossref","unstructured":"Zhang LL, Lu ZM, Zhao XX. Targeting Bcl-2 for cancer therapy. BBA-REV CANCER. 2021;1876(1).","DOI":"10.1016\/j.bbcan.2021.188569"},{"issue":"5","key":"664_CR17","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.3892\/or.2012.2000","volume":"28","author":"CY Lee","year":"2012","unstructured":"Lee CY, Chien YS, Chiu TH, Huang WW, Lu CC, Chiang JH, et al. Apoptosis triggered by vitexin in U937 human leukemia cells via a mitochondrial signaling pathway. ONCOL REP. 2012;28(5):1883\u20138.","journal-title":"ONCOL REP"},{"issue":"16","key":"664_CR18","first-page":"5161","volume":"15","author":"YJ Zhou","year":"2009","unstructured":"Zhou YJ, Liu YE, Cao JG, Zeng GY, Shen C, Li YL, et al. Vitexins, Nature-Derived Lignan compounds, induce apoptosis and suppress Tumor Growth. CCR. 2009;15(16):5161\u20139.","journal-title":"CCR"},{"issue":"4","key":"664_CR19","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.3892\/ol.2015.3618","volume":"10","author":"F An","year":"2015","unstructured":"An F, Wang SH, Tian QQ, Zhu DX. Effects of orientin and vitexin from <\u2009i\u2009>\u2009Trollius chinensis\u2009on the growth and apoptosis of esophageal cancer EC-109 cells. ONCOL LETT. 2015;10(4):2627\u201333.","journal-title":"ONCOL LETT"},{"issue":"1","key":"664_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3892\/or.2013.2855","volume":"31","author":"JG Wang","year":"2014","unstructured":"Wang JG, Zheng XX, Zeng GY, Zhou YJ, Yuan H. Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma. ONCOL REP. 2014;31(1):488\u201396.","journal-title":"ONCOL REP"},{"key":"664_CR21","doi-asserted-by":"crossref","unstructured":"Liu XL, Jiang QF, Liu HM, Luo SX. Vitexin induces apoptosis through mitochondrial pathway and PI3K\/Akt\/mTOR signaling in human non-small cell lung cancer A549 cells. BIOL RES. 2019;52.","DOI":"10.1186\/s40659-019-0214-y"},{"issue":"05","key":"664_CR22","first-page":"674","volume":"39","author":"L Geng","year":"2023","unstructured":"Geng L, wen YX, Yu Y. Vitexin inhibits the growth of human osteosarcoma cells through regulating phosphatidylinositol - 3 - kinase \/protein kinase B signaling pathway. Chin J Clin Pharmacol. 2023;39(05):674\u20138.","journal-title":"Chin J Clin Pharmacol"},{"issue":"51","key":"664_CR23","first-page":"84520","volume":"7","author":"JD He","year":"2016","unstructured":"He JD, Wang Z, Li SP, Xu YJ, Yu Y, Ding YJ, et al. Vitexin suppresses autophagy to induce apoptosis in hepatocellular carcinoma via activation of the JNK signaling pathway. OT. 2016;7(51):84520\u201332.","journal-title":"OT"},{"key":"664_CR24","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.2147\/OTT.S210077","volume":"12","author":"WB Wang","year":"2019","unstructured":"Wang WB, Cheng HB, Gu XL, Yin XD. The natural flavonoid glycoside vitexin displays preclinical antitumor activity by suppressing NF-\u03baB signaling in nasopharyngeal carcinoma. ONCOTARGETS THER. 2019;12:4461\u20138.","journal-title":"ONCOTARGETS THER"},{"key":"664_CR25","first-page":"S134","volume":"6","author":"IJ Fidler","year":"2000","unstructured":"Fidler IJ. Angiogenesis and cancer metastasis. CANCER J. 2000;6:S134\u201341.","journal-title":"CANCER J"},{"issue":"3","key":"664_CR26","first-page":"161","volume":"1","author":"JM Hou","year":"2004","unstructured":"Hou JM, Tian L, Wei YQ. Cancer Immunotherapy of Targeting Angiogenesis. CMI. 2004;1(3):161\u20136.","journal-title":"CMI"},{"issue":"2","key":"664_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/joim.12019","volume":"273","author":"L Claesson-Welsh","year":"2013","unstructured":"Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114\u201327.","journal-title":"J Intern Med"},{"key":"664_CR28","first-page":"18","volume":"8","author":"SZ Zhao","year":"2020","unstructured":"Zhao SZ, Guan XL, Hou RJ, Zhang XY, Guo F, Zhang ZF, et al. Vitexin attenuates epithelial ovarian cancer cell viability and motility\u2009<\u2009i\u2009>\u2009in vitro\u2009and carcinogenesis\u2009<\u2009i\u2009>\u2009in vivo\u2009via p38 and ERK1\/2 pathways related VEGFA. ATM. 2020;8:18.","journal-title":"ATM"},{"issue":"1","key":"664_CR29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/13880209.2023.2190774","volume":"61","author":"CX Liang","year":"2023","unstructured":"Liang CX, Jiang YJ, Sun LZ. Vitexin suppresses the proliferation, angiogenesis and stemness of endometrial cancer through the PI3K\/AKT pathway. PHARM BIOL. 2023;61(1):581\u20139.","journal-title":"PHARM BIOL"},{"issue":"4","key":"664_CR30","first-page":"86","volume":"43","author":"QQ Wang","year":"2022","unstructured":"Wang QQ, Zhang JW, Ye J, Guo J. Vitexin exerts anti-tumor and anti-angiogensis effects on cervical cancer through VEGFA\/VEGFR2 pathway. EUR J GYNAECOL ONCOL. 2022;43(4):86\u201391.","journal-title":"EUR J GYNAECOL ONCOL"},{"issue":"3","key":"664_CR31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1016-8478(23)17423-1","volume":"22","author":"HJ Choi","year":"2006","unstructured":"Choi HJ, Eun JS, Kim BG, Kim SY, Jeon H, Soh Y. Vitexin, an HIF-1\u03b1 a inhibitor, has anti-metastatic potential in PC12 cells. MOL CELLS. 2006;22(3):291\u20139.","journal-title":"MOL CELLS"},{"issue":"2","key":"664_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3892\/ijmm.2013.1587","volume":"33","author":"JG Wang","year":"2014","unstructured":"Wang JG, Zheng XX, Zeng GY, Zhou YJ, Yuan H. Purified vitexin compound 1 inhibits growth and angiogenesis through activation of FOXO3a by inactivation of akt in hepatocellular carcinoma. Int J Mol Med. 2014;33(2):441\u20138.","journal-title":"Int J Mol Med"},{"issue":"3","key":"664_CR33","doi-asserted-by":"publisher","first-page":"282","DOI":"10.2174\/1573406413666161111152720","volume":"13","author":"N Sharma","year":"2017","unstructured":"Sharma N, Akhtar S, Jamal QMS, Kamal MA, Khan MKA, Siddiqui MH, et al. Elucidation of antiangiogenic potential of Vitexin obtained from <\u2009i\u2009>\u2009Cucumis sativus\u2009Targeting Hsp90 protein: a Novel Multipathway targeted Approach to restrain angiogenic phenomena. MED CHEM. 2017;13(3):282\u201391.","journal-title":"MED CHEM"},{"issue":"3","key":"664_CR34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.semcancer.2012.02.013","volume":"22","author":"N Tiwari","year":"2012","unstructured":"Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. SEMIN CANCER BIOL. 2012;22(3):194\u2013207.","journal-title":"SEMIN CANCER BIOL"},{"issue":"3\u20134","key":"664_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10555-012-9379-3","volume":"31","author":"FY Meng","year":"2012","unstructured":"Meng FY, Wu GJ. The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. CANCER METAST REV. 2012;31(3\u20134):455\u201367.","journal-title":"CANCER METAST REV"},{"key":"664_CR36","doi-asserted-by":"crossref","unstructured":"Smith BN, Bhowmick NA. Role of EMT in Metastasis and Therapy Resistance. J Clin Med. 2016;5(2).","DOI":"10.3390\/jcm5020017"},{"issue":"4","key":"664_CR37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.5230\/jgc.2021.21.e40","volume":"21","author":"P Zhou","year":"2021","unstructured":"Zhou P, Zheng ZH, Wan T, Wu J, Liao CW, Sun XJ. Vitexin inhibits gastric Cancer Growth and Metastasis through HMGB1-mediated inactivation of the PI3K\/AKT\/mTOR\/HIF-1\u03b1 signaling pathway. J GASTRIC CANCER. 2021;21(4):439\u201356.","journal-title":"J GASTRIC CANCER"},{"key":"664_CR38","doi-asserted-by":"crossref","unstructured":"Zou SL, Tong QY, Liu BW, Huang W, Tian Y, Fu XH. Targeting STAT3 in Cancer Immunotherapy. Mol Cancer. 2020;19(1).","DOI":"10.1186\/s12943-020-01258-7"},{"issue":"5","key":"664_CR39","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2174\/156652409788488720","volume":"9","author":"E Devarajan","year":"2009","unstructured":"Devarajan E, Huang S. STAT3 as a Central Regulator of Tumor Metastases. CURR MOL MED. 2009;9(5):626\u201333.","journal-title":"CURR MOL MED"},{"key":"664_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.biochi.2020.05.006","volume":"175","author":"JH Lee","year":"2020","unstructured":"Lee JH, Mohan CD, Shanmugam MK, Rangappa S, Sethi G, Siveen KS, et al. Vitexin abrogates invasion and survival of hepatocellular carcinoma cells through targeting STAT3 signaling pathway. Biochimie. 2020;175:58\u201368.","journal-title":"Biochimie"},{"issue":"8","key":"664_CR41","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/ptr.4841","volume":"27","author":"SH Yang","year":"2013","unstructured":"Yang SH, Liao PH, Pan YF, Chen SL, Chou SS, Chou MY. The Novel p53-Dependent metastatic and apoptotic Pathway Induced by Vitexin in human oral Cancer OC2 cells. PHYTOTHER RE. 2013;27(8):1154\u201361.","journal-title":"PHYTOTHER RE"},{"key":"664_CR42","doi-asserted-by":"crossref","unstructured":"Shen XY, Zhou SC, Yang YD, Hong T, Xiang Z, Zhao J et al. TAM-targeted reeducation for enhanced cancer immunotherapy: mechanism and recent progress. FRONT ONCOL. 2022;12.","DOI":"10.3389\/fonc.2022.1034842"},{"key":"664_CR43","doi-asserted-by":"crossref","unstructured":"Chen YE, Yuan X, Pei CY, Deng ZL, Du XH, Liang J et al. Vitexin alleviates breast tumor in mice via skewing TAMs toward an iNOS\u2009<\u2009SUP>+\u2009profile orchestrating effective CD8\u2009<\u2009SUP>+\u2009T cell activation. J Funct Foods. 2022;95.","DOI":"10.1016\/j.jff.2022.105190"},{"key":"664_CR44","doi-asserted-by":"crossref","unstructured":"Chen YE, Wang BX, Yuan X, Lu YY, Hu JL, Gao J et al. Vitexin prevents colitis-associated carcinogenesis in mice through regulating macrophage polarization. Phytomedicine. 2021;83.","DOI":"10.1016\/j.phymed.2021.153489"},{"issue":"1\u20132","key":"664_CR45","first-page":"291","volume":"428","author":"H Mori","year":"1999","unstructured":"Mori H, Sugie S, Yoshimi N, Hara A, Tanaka T. Control of cell proliferation in cancer prevention. MR. 1999;428(1\u20132):291\u20138.","journal-title":"MR"},{"key":"664_CR46","doi-asserted-by":"crossref","unstructured":"Zhang LC, La XQ, Tian JM, Li HQ, Li AP, Liu YZ et al. The phytochemical vitexin and syringic acid derived from foxtail fillet bran inhibit breast cancer cells proliferation via GRP78\/SREBP-1\/SCD1 signaling axis. J Funct Foods. 2021;85.","DOI":"10.1016\/j.jff.2021.104620"},{"key":"664_CR47","doi-asserted-by":"crossref","unstructured":"Ma KW, Wang KS, Zhou YJ, Liu N, Guo W, Qi JL et al. Purified vitexin compound 1 serves as a Promising Antineoplastic Agent in Ovarian Cancer. FRONT ONCOL. 2021;11.","DOI":"10.3389\/fonc.2021.734708"},{"issue":"3","key":"664_CR48","first-page":"4599","volume":"17","author":"GN Zhang","year":"2018","unstructured":"Zhang GN, Li DY, Chen H, Zhang JC, Jin XY. Vitexin induces G2\/M-phase arrest and apoptosis via Akt\/mTOR signaling pathway in human glioblastoma cells. MOL MED REP. 2018;17(3):4599\u2013604.","journal-title":"MOL MED REP"},{"issue":"1","key":"664_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/path.2697","volume":"221","author":"D Glick","year":"2010","unstructured":"Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J PATHOL. 2010;221(1):3\u201312.","journal-title":"J PATHOL"},{"issue":"1","key":"664_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.tcb.2014.09.001","volume":"25","author":"CM Kenific","year":"2015","unstructured":"Kenific CM, Debnath J. Cellular and metabolic functions for autophagy in cancer cells. TRENDS CELL BIOL. 2015;25(1):37\u201345.","journal-title":"TRENDS CELL BIOL"},{"key":"664_CR51","doi-asserted-by":"crossref","unstructured":"Linder B, K\u00f6gel D. Autophagy in Cancer Cell Death. BIOLOGY-BASEL. 2019;8(4).","DOI":"10.3390\/biology8040082"},{"issue":"4","key":"664_CR52","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/cdd.2010.191","volume":"18","author":"R Kang","year":"2011","unstructured":"Kang R, Zeh HJ, Lotze MT, Tang D. The beclin 1 network regulates autophagy and apoptosis. CELL DEATH DIFFER. 2011;18(4):571\u201380.","journal-title":"CELL DEATH DIFFER"},{"issue":"7","key":"664_CR53","doi-asserted-by":"publisher","first-page":"947","DOI":"10.4161\/auto.6787","volume":"4","author":"JR Wang","year":"2008","unstructured":"Wang JR. Beclin 1 bridges autophagy, apoptosis and differentiation. AUTOPHAGY. 2008;4(7):947\u20138.","journal-title":"AUTOPHAGY"},{"issue":"3","key":"664_CR54","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.18632\/oncotarget.22890","volume":"9","author":"M Bhardwaj","year":"2018","unstructured":"Bhardwaj M, Cho HJ, Paul S, Jakhar R, Khan I, Lee SJ, et al. Vitexin induces apoptosis by suppressing autophagy in multi-drug resistant colorectal cancer cells. ONCOTARGET. 2018;9(3):3278\u201391.","journal-title":"ONCOTARGET"},{"issue":"9","key":"664_CR55","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1097\/CAD.0b013e328364e8d3","volume":"24","author":"J Zhou","year":"2013","unstructured":"Zhou J, Hu HY, Long JP, Wan F, Li LL, Zhang SZ, et al. Vitexin 6, a novel lignan, induces autophagy and apoptosis by activating the Jun N-terminal kinase pathway. ANTI-CANCER DRUG. 2013;24(9):928\u201336.","journal-title":"ANTI-CANCER DRUG"},{"issue":"68","key":"664_CR56","doi-asserted-by":"publisher","first-page":"112426","DOI":"10.18632\/oncotarget.20113","volume":"8","author":"M Bhardwaj","year":"2017","unstructured":"Bhardwaj M, Paul S, Jakhar R, Khan I, Kang JI, Kim HM, et al. Vitexin confers HSF-1 mediated autophagic cell death by activating JNK and ApoL1 in colorectal carcinoma cells. ONCOTARGET. 2017;8(68):112426\u201341.","journal-title":"ONCOTARGET"},{"issue":"02","key":"664_CR57","first-page":"281","volume":"39","author":"D Yuan","year":"2024","unstructured":"Yuan D, Li J, Lu YF. Inhibitory effect and mechanism of vitexin on the growth of transplanted nasopharyngeal carcinoma CNE-2 cells in nude mice based on AMPK\/ULK1 mediated autophagy. Drugs Clin. 2024;39(02):281\u20139.","journal-title":"Drugs Clin"},{"issue":"8","key":"664_CR58","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.1002\/jcp.28058","volume":"234","author":"H Mollaei","year":"2019","unstructured":"Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J CELL PHYSIOL. 2019;234(8):12369\u201384.","journal-title":"J CELL PHYSIOL"},{"issue":"10","key":"664_CR59","doi-asserted-by":"publisher","first-page":"9649","DOI":"10.1007\/s13277-014-2242-0","volume":"35","author":"WX Chen","year":"2014","unstructured":"Chen WX, Cai YQ, Lv MM, Chen L, Zhong SL, Ma TF, et al. Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs. TUMOR BIOL. 2014;35(10):9649\u201359.","journal-title":"TUMOR BIOL"},{"issue":"10","key":"664_CR60","doi-asserted-by":"publisher","first-page":"7105","DOI":"10.1074\/jbc.M112.410944","volume":"288","author":"L Morel","year":"2013","unstructured":"Morel L, Regan M, Higashimori H, Ng SK, Esau C, Vidensky S, et al. Neuronal exosomal miRNA-dependent translational regulation of Astroglial Glutamate Transporter GLT1. JBC. 2013;288(10):7105\u201316.","journal-title":"JBC"},{"issue":"15","key":"664_CR61","doi-asserted-by":"publisher","first-page":"10849","DOI":"10.1074\/jbc.M112.446831","volume":"288","author":"N Kosaka","year":"2013","unstructured":"Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T. Neutral sphingomyelinase 2 (nSMase2)-dependent Exosomal transfer of angiogenic MicroRNAs regulate Cancer Cell Metastasis. JBC. 2013;288(15):10849\u201359.","journal-title":"JBC"},{"key":"664_CR62","doi-asserted-by":"crossref","unstructured":"Peng JC, Li S, Li B, Hu WX, Ding CM. Exosomes derived from M1 macrophages inhibit the proliferation of the A549 and H1299 lung cancer cell lines via the miRNA-let-7b-5p-GNG5 axis. PeerJ. 2023;11.","DOI":"10.7717\/peerj.14608"},{"key":"664_CR63","doi-asserted-by":"crossref","unstructured":"Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. RB. 2019;25.","DOI":"10.1016\/j.redox.2018.101084"},{"key":"664_CR64","doi-asserted-by":"crossref","unstructured":"Zhao YX, Ye XC, Xiong ZF, Ihsan A, Ares I, Mart\u00ednez M et al. Cancer Metabolism: The Role of ROS in DNA Damage and Induction of Apoptosis in Cancer Cells. METABOLITES. 2023;13(7).","DOI":"10.3390\/metabo13070796"},{"key":"664_CR65","doi-asserted-by":"crossref","unstructured":"Liu NA, Wang KS, Qi M, Zhou YJ, Zeng GY, Tao J et al. Vitexin compound 1, a novel extraction from a Chinese herb, suppresses melanoma cell growth through DNA damage by increasing ROS levels. J EXP CLIN CANC RES. 2018;37.","DOI":"10.1186\/s13046-018-0897-x"},{"issue":"7","key":"664_CR66","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1007\/s12094-019-02234-4","volume":"22","author":"T Xie","year":"2020","unstructured":"Xie T, Wang JR, Dai CG, Fu XA, Dong J, Huang Q. Vitexin, an inhibitor of hypoxia-inducible factor-1\u03b1, enhances the radiotherapy sensitization of hyperbaric oxygen on glioma. CLIN TRANSL ONCOL. 2020;22(7):1086\u201393.","journal-title":"CLIN TRANSL ONCOL"},{"key":"664_CR67","doi-asserted-by":"crossref","unstructured":"Xie T, Ding YH, Sang CS, Lin ZX, Dong J, Fu XA. Vitexin enhances radiosensitivity of mouse subcutaneous xenograft glioma by affecting the miR-17-5p\/miR-130b-3p\/PTEN\/HIF-1\u03b1 pathway. CLIN TRANSL ONCOL. 2024;200(6):535\u2013\u200943.","DOI":"10.1007\/s00066-024-02220-y"},{"key":"664_CR68","doi-asserted-by":"crossref","unstructured":"Chen DS, Chen Y, Huang F, Zhang XL, Zhou YL, Xu LN. The underlying regulatory mechanisms of colorectal carcinoma by combining Vitexin and Aspirin: based on systems biology, molecular docking, molecular dynamics simulation, and <\u2009i\u2009>\u2009in vitro\u2009study. Front Endocrinol. 2023;14.","DOI":"10.3389\/fendo.2023.1147132"},{"key":"664_CR69","doi-asserted-by":"crossref","unstructured":"Cao X, Liu Q, Adu-Frimpong M, Shi WW, Liu K, Deng TW et al. Microfluidic Generation of Near-Infrared Photothermal Vitexin\/ICG Liposome with amplified photodynamic therapy. AAPS. 2023;24(4).","DOI":"10.1208\/s12249-023-02539-2"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00664-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-024-00664-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00664-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T01:55:02Z","timestamp":1737338102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-024-00664-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["664"],"URL":"https:\/\/doi.org\/10.1007\/s43440-024-00664-8","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}